US FDA approves J&J’s Rybrevant plus standard of care as first …
WEB1 day ago · US FDA approves J&J’s Rybrevant plus standard of care as first and only targeted regimen to cut risk of disease progression by more than half in second-line EGFR-mutated advanced lung cancer
New Novartis data in relapsing MS reinforce benefits of Kesimpta …
WEB2 days ago · Friday, September 20, 2024, 12:00 Hrs [IST] Novartis announced new data from the ALITHIOS open-label extension study. Data show first-line Kesimpta (ofatumumab) treatment for up to six years led to less disability and disease progression in recently diagnosed (=3 years) and treatment-naïve (RDTN) …
Astellas Pharma announces US FDA listing of DIGITIVA for the …
WEB2 days ago · Tokyo. Friday, September 20, 2024, 11:00 Hrs [IST] Astellas Pharma Inc. announced that DIGITIVA, a non-invasive digital health solution for heart failure management, has been listed with the US Food and Drug Administration (FDA). DIGITIVA is classified as a Class I Software as a Medical Device (SaMD) and is exempt from 510 (k) premarket submission.
Roche announces phase III CENTERSTONE study of Xofluza …
WEB2 days ago · Roche announced positive topline results of the phase III CENTERSTONE study of Xofluza (baloxavir marboxil), an antiviral, showing a reduction in the transmission of influenza viruses. The study met its primary endpoint, demonstrating that a single, oral dose of Xofluza taken by people infected with ...
US FDA approves Roche’s Ocrevus Zunovo to treat relapsing …
WEB5 days ago · Basel. Tuesday, September 17, 2024, 10:00 Hrs [IST] Roche announced that the United States Food and Drug Administration (FDA) has approved Ocrevus Zunovo (ocrelizumab & hyaluronidase-ocsq) for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). Ocrevus Zunovo is …
US FDA grants Emergency Use Authorization to Novavax 2024 …
WEBSep 2, 2024 · Novavax, Inc., a global company advancing protein-based vaccines with its Matrix-M adjuvant, announced the Novavax Covid-19 Vaccine, Adjuvanted (2024-2025 Formula) (NVX-CoV2705) has received Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) for active immunization to ...
JB Pharma accelerates global expansion and diversifies into …
WEB3 days ago · JB Pharma has announced significant strides in its strategic growth, diversifying into progressive therapies while strengthening its presence in international markets. Over the past three years, the company has seen robust growth, with revenue increasing at a 19% compound annual growth rate (CAGR ...
Pfizer, BioNTech receive US FDA approval & authorization for …
WEBSaturday, August 24, 2024, 09:00 Hrs [IST] Pfizer Inc. and BioNTech SE announced that the US Food and Drug Administration (FDA) has approved the supplemental Biologics License Application for individuals 12 years of age and older (COMIRNATY (Covid-19 Vaccine, mRNA), and granted emergency use authorization for individuals 6 …
News - Pharmabiz.com
WEB4 days ago · Pharmabiz.com - India's most comprehensive online pharma news service. It provides updates on Indian pharma industry, allied sectors like hospitals & diagnostic services,pharma tenders, pharma projects, pharma export & import, pharma laws & documents, pharma policies, pharma events, pharma company profiles, pharma studies, pharma marketing.
Boehringer Ingelheim’s Cyltezo to treat multiple chronic …
WEBFriday, May 3, 2024, 11:00 Hrs [IST] Boehringer Ingelheim Group, one of the largest producers of biologic medicines in the world, announced that the US Food and Drug Administration (FDA) has approved the high-concentration, citrate-free formulation of Cyltezo (adalimumab-adbm), the company's interchangeable biosimilar to Humira (adalimumab), to ...
Skip to content